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Abstract 
Background & Aims 
n-3 polyunsaturated fatty acids (PUFA) ameliorate fatty liver in experimental models, but their 
effects on inflammation and fibrosis during steatohepatitis are either controversial or lacking. We 
compared the effects of supplementation with olive oil (OO) alone or OO and n-3 PUFA on the 
development and progression of experimental steatohepatitis. 
Methods 
Balb/C mice (≥5 mice/group) were fed a methionine- and choline-deficient (MCD) diet or a control 
diet for 4 or 8 weeks. At the same time, mice were supplemented with n-3 PUFA (eicosapentaenoic 
and docosahexahenoic acid, 25 mg together with 75 mg OO), or OO alone (100 mg), two times a 
week by intragastric gavage. 
Results 
After 8 weeks, mice on MCD/n-3 had higher ALT levels compared to MCD/OO and more severe 
scores of inflammation, including a significant increase in the number of lipogranulomas 
(26.4 ± 8.4 vs. 5.1 ± 5 per field, P < 0.001). Intrahepatic expression of TNF-α and CCL2 was higher 
in MCD/n-3 mice at both time points. In addition, increased expression of the profibrogenic genes 
TIMP-1 and TGF-β, and more severe histological scores of fibrosis were evident in MCD/n-3 mice. 
After 8 week of MCD diet, portal pressure was higher in mice receiving n-3 than in those on OO 
alone (5.1 ± 1.4 vs. 7.0 ± 0.9 mmHg, P < 0.05). Analysis of hepatic fatty acid profile showed that 
supplementation resulted in effective incorporation of n-3 PUFA. 
Conclusions 
In a murine model of steatohepatitis, supplementation with n-3 PUFA and OO is associated with 
more severe necro-inflammation and fibrosis than in mice treated with OO only. 
  
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic hepatic damage in 
Western countries [1]. The clinical implications of NAFLD are because of its common occurrence 
in the general population and its potential to progress to cirrhosis, liver failure and hepatocellular 
carcinoma [2]. Nonalcoholic steatohepatitis (NASH) is observed in a subset of patients with 
NAFLD and is characterized by lobular and portal inflammation, signs of hepatocellular damage 
such as ballooning, and development of fibrosis [3]. The causes of progression to steatohepatitis 
remain unclear, but lipotoxicity, oxidative stress and an imbalance in the pattern of pro- and anti-
inflammatory cytokines are believed to play key roles [4, 5]. 
It is well established that excessive calorie consumption and obesity are risk factor for the 
development of NAFLD and its progression to fibrosis [1]. However, data on the role of different 
nutrients are scanty and often controversial, particularly with respect to the role of fatty acids. 
Studies in a population of NASH patients have shown a lower consumption of omega-3 
polyunsaturated fatty acids (n-3 PUFA) compared to a control population [6]. n-3 PUFA are found 
naturally in fish oil, flaxseed and some nuts, and mainly occur as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), which generally have anti-inflammatory properties [7]. Moreover, 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been associated with the 
prevention and treatment of cardiovascular, inflammatory and autoimmune diseases [8, 9]. 
Several lines of evidence support a possible beneficial role of n-3 PUFA in NAFLD (reviewed in 
Refs [10, 11]). On the one hand, n-3 PUFAs promote fatty acid oxidation by binding and activating 
peroxisome proliferator activated receptor α (PPARα) [11]. On the other hand, n-3 PUFAs suppress 
lipogenesis by inhibiting sterol regulatory element binding protein-1c (SREBP-1c) expression [12], 
decrease hepatic oxidative stress [13] and suppress production of pro-inflammatory cytokines [14]. 
However, whether n-3 PUFA may have a positive effect on the development of NASH and fibrosis 
has not been fully clarified. 
In this study, we analysed the effects of supplementation with two combinations of fatty acids, 
including OO alone or associated with n-3 PUFA, on the development of experimental nonalcoholic 
steatohepatitis caused by administration of a methionine- and choline-deficient (MCD) diet. Our 
data demonstrate that addition of n-3 PUFA results in enhanced inflammation and more severe 
development of fibrosis. 
Materials and methods 
Animals and protocol 
Male Balb/C mice weighing between 20 and 25 g were purchased from Charles River Laboratories 
(Calco, Italy). All animals, 8 weeks of age at the beginning of this study, were housed four or five 
per cage and kept under a controlled temperature of 22 ± 2°C, 50–60% relative humidity and 12 h 
light/dark cycles. Mice had free access to food and water ad libitum and were weighed at weekly 
intervals throughout the experiment. Mice were fed either a high-fat diet deficient in methionine 
and choline (MCD diet, containing 58% of energy derived from fat, 18% from protein and 24% 
from carbohydrates, 5.6 kcal/g) or a control diet supplemented with methionine and choline (CD 
containing 5% of energy derived from fat, 18% from proteins and 77% from carbohydrates; 
3.3 kcal/g). Diets were prepared by Dottori Piccioni Laboratories (Milan, Italy) and stored at 4°C 
until used. Experimental animals receiving the different diets were further subdivided to receive 
either n-3 PUFA (eicosapentenoic and docosahexahenoic acid, 25 mg, together with 75 mg OO) or 
100 mg OO twice weekly by intragastric gavage. Fatty acids (Società Prodotti Antibiotici, Italy) 
were provided as oil in capsules. Before each administration, a new capsule was punctured with a 
syringe equipped with a fine needle and administered to animals. Four to eight animals were 
included in each experimental group (Cnt − OO, Cnt − n-3 PUFA, MCD − OO, MCD − n-3 PUFA). 
Mice were euthanized at 4 or 8 weeks by exsanguination under anaesthesia with an i.p. injection of 
80 mg/kg 50% tiletamine hydrochloride and 50% zolazepam hydrochloride (Virbac, Carros, 
France). Body weight was recorded and blood was collected from the inferior vena cava, 
centrifuged and serum stored for further analysis. Livers were rapidly dissected out, weighed, snap 
frozen in liquid nitrogen and kept at −80°C for RNA and protein extraction. A portion of the liver 
was immediately fixed in formalin for histological analyses. All animals received humane care, and 
experimental protocols were conducted according to established international guidelines (Guide for 
the Care and Use of Laboratory Animals, NIH publication No. 86-23) after approval by the local 
regulatory authorities. 
Serum aminotransferase levels 
Blood samples were centrifuged at 1500g for 10 min at 4°C to obtain serum that was kept at −20°C 
until analysed. Serum amino transferase activity was determined using a commercially available kit 
(DiaSys Diagnostic Systems GmbH, Holzheim, Germany). 
Liver histology 
A portion of liver tissue was fixed by immersion in 10% buffered formalin (pH 7.4) for 24 h. The 
fixed tissue was dehydrated in graded ethanol, paraffin embedded and sectioned at a thickness of 
4 μm. Haematoxylin–eosin and Sirius Red stainings were performed as previously described [15] 
and liver histology was evaluated by an experienced hepatopathologist (S.M.) blinded to the type of 
treatment received by the animals. Necro-inflammation was graded focusing on zone 3 as 0 
(absent), 1 (sparse or mild, focal), 2 (noticeable) and 3 (severe). In addition, the number of 
lipogranulomas was quantified separately. Quantification of fibrosis and steatosis was performed by 
histomorphometric analysis using a digital camera (DFC 320; Leica, Wetzlar, Germany) coupled to 
a bright field microscope (DM4000; Leica). Three randomly selected fields (×10 magnification) of 
haematoxylin–eosin or picrosirius red-stained liver slides (5 μm sections) were scored in three 
sections of each animal at a final magnification of ×100. 
RNA isolation and quantitative PCR 
Total RNA from liver tissue was isolated with an RNeasy mini kit (Qiagen, Hilden, Germany), 
according to the manufacturer's instructions. Total RNA (5 μg) from each sample was reverse 
transcribed to complementary DNA (cDNA) using the SuperScript III first strand synthesis system 
(Invitrogen, Grand Island, NY, USA), according to the manufacturer's instructions. Hepatic mRNA 
gene expression was evaluated using quantitative real-time RT-PCR with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as housekeeping gene. Quantitative real-time RT-PCR and 
analysis were performed using a Corbett Rotorgene 6600 analyzer (Corbett Life Science, Sydney, 
Australia). FAM-labelled probes and specific primers were obtained as Assays-on-Demand 
(Applied Biosystems, Foster City, CA, USA). Relative gene expression was calculated as 2
−ΔCt
 
(ΔCt = Ct of the target gene minus Ct of GAPDH). A list of the primers used in this study is reported 
in Table S1. 
Determination of oxidative stress in liver tissue 
Intrahepatic levels of 8-hydroxy-2-deoxyguanosine (8-OHdG), a well-established marker of 
oxidative DNA damage [16] were determined by immunohistochemistry as previously described 
[17]. Morphometric assessment was performed using an optic microscope (Eclipse E600; Nikon, 
Tokyo, Japan) connected to a high-resolution camera (CC12 Soft-Imaging System, Münster, 
Germany). 
Measurement of portal pressure 
After 8 weeks of treatment, the portal vein of anaesthetized mice was cannulated through an 
ileocolic vein with a PE-10 catheter. This catheter was connected to a highly sensitive pressure 
transducer, and blood pressure was registered on multichannel recorder. 
Analysis of the hepatic fatty acid profile 
Liver tissue was suspended in 0.25 M sucrose, 20 mM Tris HCl, pH 7.4 (1:2.5 w/v), homogenized 
with a Ultra-Turrax homogenizer (IKA, Milan, Italy) and finally diluted to 10% (v:v) with the same 
solvent. Total lipids were recovered from homogenate aliquots containing 15 mg of protein using 
chloroform–methanol (2:1) with the addition of 0.01% 2,6-Di-ter-butyl-4-methylphenol as 
antioxidant [18]. 
Lipid extracts were spiked with 50 μg of margaric acid methyl ester (C 17:0) as internal standard, 
and fatty acid methyl esters were prepared following the method of Metcalfe et al. [19]. After 
methylation, fatty acid methyl esters were redissolved in a 1:10 (v/v) ether:chloroform solution. 
Fatty acid methyl ester analysis was performed with an Agilent 6890A gas chromatograph equipped 
with a quadrupole mass spectrometer (Agilent 5973) and a CP-Wax 52 CB capillary column (30 
metre length, 0.32 mm ID, 0.5 μm phase thickness, Agilent). Operating conditions were as follows: 
carrier He at 2 ml/min, Inlet 260°C, splitless injection with pulsed pressure (14 psi for 1 min), 
injected volume 1 μl. Column oven was at 50°C for 2 min, then to 200°C at 20°C/min, then to 
230°C at 3°C/min. Mass spectrometer was operated in scan mode (29–400 Th). Peaks were 
identified by comparison of retention times and mass spectra with known fatty acid methyl ester 
standards and are expressed as percentage of total fatty acids. 
Statistical analysis 
Unless stated otherwise, data are expressed as mean ± SD. Comparisons of animals treated with OO 
or n-3 PUFA and the effects of the MCD diet were performed by Student's t-test. Histological 
scores of inflammation and fibrosis were compared using the Mann–Whitney U-test. P values less 
than 0.05 were considered significant. 
 
Results 
The MCD diet model is characterized by the rapid appearance (after 2-4 weeks) of steatosis, 
inflammation and cell death, which represent the cardinal features of steatohepatitis. After 
prolonged administration of the steatogenic diet (8 weeks), steatohepatitis is associated with 
fibrosis, which is localized predominantly in the perivenular area (zone 3 of the hepatic acinus). 
After 4 weeks of MCD diet administration, mice showed a marked decrease in body weight in 
comparison to animals fed the Cnt diet, as previously described in this model (Table 1). In mice 
treated with n-3 PUFA, liver weight was significantly higher than in those exposed to OO, resulting 
in a slight but significant increase in the liver/weight ratio. In contrast, after 8 weeks, body weight, 
liver weight and the liver/body weight ratio were all significantly reduced in MCD-n-3 mice as 
compared to MCD-OO. Only minor changes were associated with PUFA administration in mice 
receiving the Cnt diet. 
Table 1. Body and liver weight during the experimental protocol 
  Body weight (g) Liver weight (g) Liver/body weight (%) 
1. Mice were administered a methionine- and choline-deficient diet (MCD) or an identical diet 
supplemented with methionine and choline (CD) and treated with olive oil alone (OO) or 
together with an admixture of omega-3 fatty acids (n-3). At the time of sacrifice, body and 
liver weight were recorded. Data are mean ± SD. 
2. *P < 0.05 vs. CD + OO; **P < 0.05 vs. MCD + OO; ***P = 0.07 vs. MCD + OO. 
4 weeks 
Cnt + OO 24.08 ± 2.44 1.65 ± 0.25 6.83 ± 0.39 
Cnt + n-3 23.4 ± 4.75 2.11 ± 0.11* 8.17 ± 0.15* 
MCD + OO 14.82 ± 1.52 1.11 ± 0.23 7.54 ± 1.72 
MCD + n-3 14.85 ± 0.78 1.28 ± 0.07** 8.63 ± 0.62*** 
8 weeks 
Cnt + OO 29.00 ± 1.73 1.52 ± 0.16 5.24 ± 0.24 
Cnt + n-3 28.67 ± 1.15 1.33 ± 0.06 4.64 ± 0.30* 
MCD + OO 16.40 ± 0.82 1.20 ± 0.23 7.28 ± 1.15 
MCD + n-3 13.29 ± 1.21** 0.68 ± 0.12** 5.14 ± 0.85** 
We next evaluated the effects of supplementation with the different types of fatty acids on the 
cardinal aspects of steatohepatitis, analysing serum biochemistry and histological damage. 
Administration of the MCD diet resulted in a marked elevation of serum ALT and AST compared 
to animals receiving the Cnt diet, with a 5- to 10-fold increase after 4 weeks (Fig. 1A). At this time 
point, no significant differences were observed comparing mice supplemented with n-3 PUFA OR 
OO. After 8 weeks, ALT and AST levels were markedly decreased in MCD-OO mice and appeared 
to be only modestly increased compared to mice receiving the Cnt diet. In contrast, 
aminotransferase levels remained markedly and significantly higher in MCD-n-3 mice, with levels 
similar to the ones observed after 4 weeks (Fig. 1B). 
 Figure 1.  
 
Effects of fatty acid supplementation on aminotransferase levels in mice administered a MCD diet. 
Mice were administered a control diet (Cnt) or a diet without methionine and choline (MCD) for 
4 weeks (panel A) or for 8 weeks. During the entire protocol, mice were administered with olive oil 
(black columns) or with a mixture of 25% n-3 PUFA in olive oil (cross-hatched columns). At the 
end of the experiment, plasma levels of ALT and AST, as indicated, were measured. *P < 0.05 vs. 
olive oil. 
To correlate the increase in aminotransferase levels with the actual histological damage, liver 
sections were stained with haematoxylin and eosin and scored by an experienced pathologist 
(Figs. 2 and 3). At both 4 and 8 weeks, the MCD diet induced marked steatosis, mainly 
macrovescicular, predominantly in the perivenular area (Fig. 2). Semiquantitative scoring (Fig. 3A) 
demonstrated the presence of mild to moderate steatosis throughout this study protocol. However, 
no significant differences in the severity of steatosis were observed comparing animals 
supplemented with the two types of fatty acids, at both time points tested. We next evaluated the 
extent of inflammatory infiltration associated with the MCD diet. At both 4 and 8 weeks, the 
amount of inflammatory cells in the liver was markedly increased, as indicated by the histological 
score (Fig. 3A). In mice administered n-3 PUFA together with the MCD diet, the overall 
inflammatory score was higher than that of mice treated with OO at both 4 and 8 weeks, although 
differences did not reach statistical significance. Inflammation in the MCD model is also 
characterized by the appearance of lipogranulomas, where clusters of inflammatory cells surround 
small groups of fat-laden hepatocytes (Fig. 2). In mice fed the MCD diet together with n-3 PUFA, 
lipogranulomas appeared at 4 weeks and were abundantly present after 8 weeks of treatment 
(Figs. 2 and 3B). In contrast, mice receiving OO together with the MCD diet had no lipogranulomas 
at 4 weeks and their number was markedly and significantly lower than in MCD-n-3 mice at 
8 weeks. These data indicate that supplementation with n-3 PUFA is associated with a more severe 
biochemical and histological phenotype in MCD-induced steatohepatitis. 
 Figure 2.  
 
Effects of fatty acid supplementation on liver histology in mice administered a MCD diet. Mice 
were administered a control diet (panels A–B) or a diet without methionine and choline for 4 weeks 
(panels C–F) or 8 weeks (panels G–H). During the entire protocol, mice were administered with 
olive oil (panels A,C,E,G) or with a mixture of 25% n-3 PUFA in olive oil (panels B,D,F,H). 
Paraffin-embedded liver sections were stained with haematoxylin and eosin. Original magnification 
×40 (panels A–D) or ×80 (panels E–H). 
 Figure 3.  
 
Fatty acid supplementation differentially affects the development of inflammation in MCD-induced 
steatohepatitis. Mice were administered a control diet (Cnt) or a diet without methionine and 
choline (MCD) for 4 weeks or 8 weeks. During the entire protocol, mice were administered with 
olive oil (OO) or with a mixture of 25% n-3 PUFA in olive oil (n-3). Panel A: Necroinflammatory 
score was measured by an investigator blinded to the identity of specimens, as indicated in 
Materials and Methods. Each point represents an individual animal. Panel B: The number of 
lipogranulomas, defined as indicated in Materials and Methods, was measured in 10 high-power 
fields in each group of mice. Black columns: olive oil. Cross-hatched columns: n-3 PUFA. 
*P < 0.05 vs. olive oil. 
To provide a functional counterpart to the increased necroinflammatory damage observed at both 
biochemical and histological levels, we evaluated the intrahepatic expression of a panel of genes 
known to be related to liver inflammation (Fig. 4). The surface marker CD11b, that is expressed by 
monocytes and other activated leucocytes, increased in mice treated with MCD at both time points 
(Fig. 4). However, comparing the expression levels according to the type of PUFA supplementation 
received, mice treated with OO had consistently and significantly lower expression of CD11b. 
Similar results were obtained when expression of TNF-alpha, a pivotal cytokine in the pathogenesis 
of inflammatory damage, was assessed (Fig. 4). Finally, the transcript levels of CCL2, an 
inflammatory chemokine closely involved in hepatic inflammatory injury [20], were also 
significantly higher in MCD-n-3 mice than in the corresponding OO-fed animals (Fig. 4). Taken 
together, these data indicate that the inflammatory response is increased when a diet inducing 
steatohepatitis is associated with supplementation with n-3 PUFA. Along these lines, it is well 
established that steatohepatitis is associated with generation of reactive oxygen species and other 
oxidative stress-related compounds. To evaluate the possible differential effects of the two 
supplementations on redox-related changes, we measured by immunohistochemistry the number of 
nuclei positive for 8-hydroxy-deoxyguanosine, as an indicator of oxidative stress-induced DNA 
modifications [16]. While staining was virtually absent in mice administered the Cnt diet (Fig. S1), 
a marked increase was observed upon administration of the MCD diet. In mice supplemented with 
n-3 PUFA, the percentage of positive cells was slightly, but not significantly higher than in mice 
receiving OO. 
 
Figure 4.  
Effects of fatty acid supplementation on hepatic expression of inflammation-related genes in mice 
administered a MCD diet. Mice were administered a control diet (Cnt) or a diet without methionine 
and choline (MCD) for 4 weeks or 8 weeks, as indicated. During the entire protocol, mice were 
administered with olive oil (black columns) or with a mixture of 25% n-3 PUFA in olive oil (cross-
hatched columns). Expression of the indicated genes was measured by quantitative real time on 
liver RNA as indicated in Materials and Methods. *P < 0.05 vs. olive oil. 
The MCD diet model in rodents has the ability to nicely reproduce the development of perivenular 
fibrosis observed in human steatohepatitis, although the pathogenesis of liver injury is at least 
partially different. After 4 weeks of MCD diet, fibrosis was barely evident irrespectively of the type 
of fatty acids supplemented (Fig. 5A–F). In contrast, a clear perivenular fibrosis, with the typical 
‘chickenwire’ pattern, was evident after 8 weeks (Fig. 5F–I). The extent of extracellular matrix 
deposition, as evidenced by Sirius red staining, was more abundant after supplementation with n-3 
PUFA than with OO. To further evaluate this finding, semiquantitative histological fibrosis scores 
were measured. While fibrosis was found to be mild (stage 1) in nearly all MCD-OO mice, 
administration of n-3 PUFA together with the MCD diet resulted in a marked increase in the 
observed stage of fibrosis (Fig. 6A). In contrast, no differences in the degree of steatosis were found 
in mice treated with the different supplementation protocols (Fig. 6B). 
 
Figure 5.  
Effects of fatty acid supplementation on the development of fibrosis in mice administered a MCD 
diet. Mice were administered a control diet (panels A–B) or a diet without methionine and choline 
for 4 weeks (panels C–F) or 8 weeks (panels G–J). During the entire protocol, mice were 
administered with olive oil (panels A,C,E,G,I) or with a mixture of 25% n-3 PUFA in olive oil 
(panels B,D,F,H, J). Paraffin-embedded liver sections were stained with Sirius red, as described in 
'Materials and methods'. Original magnification ×40 (panels A,B,C,D,G,H) or ×80 (panels E,F,I,J). 
 
Figure 6.  
 
Effects of fatty acid supplementation on the histological scores of fibrosis and steatosis in MCD-
induced steatohepatitis. Mice were administered a control diet (Cnt) or a diet without methionine 
and choline (MCD) for 4 weeks or 8 weeks. During the entire protocol, mice were administered 
with olive oil (OO) or with a mixture of 25% n-3 PUFA in olive oil (n-3). Histological scores were 
measured by an investigator blinded to the identity of specimens, as indicated in Materials and 
Methods. Each point represents an individual animal. Panel A: Score of fibrosis after 8 weeks of 
Cnt or MCD diet: the score with the MCD diet was significantly different comparing OO and n-3 
(P < 0.05). Panel B: score of steatosis after 4 or 8 weeks of MCD diet, as indicated. 
We next investigated whether the more severe fibrosis observed in MCD-n-3 mice was associated 
with differential expression of profibrogenic genes. MCD diet caused an increase in intrahepatic 
expression of transforming growth factor (TGF)-β, tissue inhibitor of metalloproteinase (TIMP)-1 
and type I procollagen, both at 4 and 8 weeks (Fig. 7). At 4 weeks, the expression levels of TGF-β 
and TIMP-1 were significantly higher in MCD-n-3 mice than in the MCD-OO group. Interestingly, 
these differences were no longer evident at the 8-week time point, although these genes were still 
up-regulated with respect to the control groups. 
 
Figure 7.  
Effects of fatty acid supplementation on hepatic expression of fibrogenesis-related genes in mice 
administered a MCD diet. Mice were administered a control diet (Cnt) or a diet without methionine 
and choline (MCD) for 4 weeks or 8 weeks, as indicated. During the entire protocol, mice were 
administered with olive oil (black columns) or with a mixture of 25% n-3 PUFA in olive oil (cross-
hatched columns). Expression of the indicated genes was measured by quantitative real-time on 
liver RNA as indicated in Materials and Methods. *P < 0.05 vs. olive oil. 
To evaluate whether changes in the fibrotic stage were paralleled by similar changes in portal 
pressure, this parameter was measured shortly before sacrifice at the 8-week time point of this study 
(Fig. 8). While portal pressure was only modestly changed in MCD-OO mice, its values were 
significantly more elevated in the MCD-n-3 group. In aggregate, these data demonstrate that 
supplementation of mice fed a MCD diet with n-3 PUFA together with olive oil results in faster 
hepatic fibrogenesis and disease progression compared to mice supplemented with olive oil only. 
 Figure 8.  
Effects of fatty acid supplementation on portal pressure in mice administered a MCD diet. Mice 
were administered a control diet (Cnt) or a diet without methionine and choline (MCD) for 8 weeks. 
During the entire protocol, mice were administered with olive oil (black columns) or with a mixture 
of 25% n-3 PUFA in olive oil (cross-hatched columns). At the end of the experiments portal 
pressure was measured as indicated in Materials and Methods. *P < 0.05 vs. olive oil. 
Administration of the MCD diet is associated with weight loss and wasting, and development of 
steatosis is mostly related to the inadequate secretion of VLDL, rather than on an increase inflow of 
free fatty acids [21]. For this reason, we tested whether supplementation with the different mixtures 
of fatty acids was effective in modifying the intrahepatic lipid profile, analysing the fatty acid 
profile of the different groups of mice treated for 8 weeks (Fig. 9). In mice treated with the control 
diet, the fatty acid profile was remarkably stable, and only very minor differences were observed. In 
contrast, mice treated with the MCD diet and receiving OO had a significantly increased percentage 
of oleic acid (18:1 n-9) in liver lipids. Similarly, a significant increase in all fatty acids of the n-3 
series was observed in mice receiving n-3 PUFA. Of note, the levels of 20:5 n-3 (eicosapentaenoic 
acid) and those of its elongation and desaturation products, 22:5 and 22:6 n-3 were significantly 
increased in the liver of mice receiving n-3 PUFA. These data indicate that the supplementation 
protocol was able to induce corresponding changes at the intrahepatic level, ruling out the 
possibility of a lack of effect because of the simultaneous administration of a MCD diet. To further 
demonstrate that the fatty acid supplementation was functionally effective, the expression levels of 
PPAR-α, which are up-regulated by n-3 PUFA [22], were measured (Fig. S2). Supplementation 
with n-3 PUFA resulted in the expected significant increase in PPAR-α expression, indicating that 
the protocol was functionally effective on the liver. 
 Figure 9.  
Effects of fatty acid supplementation on the hepatic fatty acid profile in mice administered a MCD 
diet. Mice were administered a control diet (Cnt) or a diet without methionine and choline (MCD) 
for 4 weeks or 8 weeks, as indicated. During the entire protocol, mice were administered with olive 
oil (OO) or with a mixture of 25% n-3 PUFA in olive oil (n-3). At the end of the experiment, the 
fatty acid profile of hepatic lipids was analysed as described in 'Materials and methods'. *P < 0.05 
vs. control diet with the same supplement; 
#
P < 0.05 vs. olive oil. 
Discussion 
The effects of specific nutrients on the development of nonalcoholic steatohepatitis remain largely 
unknown. Recent studies have highlighted the fact that specific sugars and aminoacids are 
associated with modulation of inflammation and fibrogenesis in different experimental models [23]. 
The presence of dyslipidemia, intrahepatic triglyceride accumulation, and expansion of the liver 
free fatty acid pool has generated considerable interest on the role of different types of fatty acids 
introduced with the diet in the modulation of steatohepatitis. The results of the present study 
demonstrate that supplementation with two mixtures of fatty acids differentially affects 
inflammation and fibrogenesis in a model of murine nonalcoholic steatohepatitis. Specifically, 
supplementation with a 25/75% mixture of n-3 PUFA and olive oil resulted in a more severe 
inflammatory phenotype and worsened fibrogenesis in comparison to mice receiving an equal 
amount of fatty acids in the form of 100% OO. Enhanced inflammation and injury in animals 
receiving n-3 PUFA is demonstrated by several lines of evidence. First, aminotransferase levels 
were more elevated than in mice receiving OO alone, after 8 weeks of administration of a MCD 
diet. These biochemical changes were accompanied by histological evidence of increased hepatic 
injury, as indicated by the higher necroinflammatory score. In addition, intrahepatic expression of 
genes related to inflammatory pathways was markedly and significantly elevated, including CD11b, 
expressed on activated leucocytes. A particular aspect of the inflammatory process in n-3 PUFA-
treated mice was the dramatic increase in the number of lipogranulomas, inflammatory foci where 
clusters of leucocytes surround lipid-laden hepatocytes often undergoing apoptosis. These changes 
were already evident in n-3 PUFA-treated mice on a MCD diet after 4 weeks, but became almost 6-
fold more abundant at the 8-week time point. Lipogranulomas may represent areas in which 
inflammation is more strictly associated with hepatocellular damage, and their appearance was 
temporally associated with a more evident elevation in ALT and higher expression of pro-
inflammatory cytokines. 
The interaction of n-3 PUFA with inflammation has received considerable attention in recent years, 
both in the liver and in other tissues. The general understanding is that this class of lipids exerts 
anti-inflammatory actions in a variety of conditions, acting on several signalling pathways including 
the newly identified metabolites collectively indicated as ‘resolvins’ [24, 25]. This anti-
inflammatory action has been confirmed in different conditions of liver injury, including the MCD 
and other dietary models of steatohepatitis [26-28]. However, other studies have shown that 
supplementation with PUFA has detrimental effects on inflammation in models of steatohepatitis. 
Lee et al. [29] modified the content of PUFA in the MCD diet and found that an increased amount 
of these fatty acids is associated with increased inflammation. Of note, no worsening of 
hepatocellular injury was reported, indicating a selective effect of PUFA on inflammation, but not 
on hepatocellular damage. Moreover, no information on the possible specific role of n-3 fatty acids 
was provided. In another study [22], enrichment of a MCD diet with fish oil, mostly composed of n-
3 PUFA, caused a more severe inflammatory phenotype than olive oil. Moreover, in alcoholic 
steatohepatitis, administration of PUFA, including n-3 fatty acids, has been associated with more 
severe hepatic damage and worsening of oxidative stress [30]. The MCD model is extremely 
sensitive to oxidative stress, as the lack of methionine supply limits the formation of the potent 
antioxidant, glutathione [31]. However, in the present study, no differences were found concerning 
oxidative stress when comparing mice treated with a MCD diet and receiving the two different 
supplementation protocols. While these data suggest that oxidative stress may not be critical in 
determining the more severe inflammatory phenotype of n-3 PUFA-treated mice, it is possible that 
other components of the oxidative stress, e.g. reactive aldehydes, were differentially regulated. 
Alternatively, it is possible that the already high levels of DNA oxidation could not be further and 
sensitively modulated by the different fatty acid formulations. Of note, in the Larter study [22], fish 
oil supplementation was found to markedly increase the levels of hydroperoxides, although no 
changes in the levels of arachidonic acid metabolites or NF-κB activation could be found, and the 
pro-inflammatory cytokine profile was not tested. 
Several lines of information obtained in our study may be important to shed additional light on the 
controversy between studies showing protective vs. detrimental effects of n-3 PUFA on 
experimental steatohepatitis published in the last decade. First, unlike any other published study, 
fatty acid supplementation was provided by gavage, in a strictly controlled dosing and timing, and 
not as enrichment of a diet the consumption of which may vary with time and with the deterioration 
of the animal conditions. Second, we performed analysis of the fatty acid profile of hepatic lipids to 
establish whether the supplementation protocol was successful in modifying its composition. 
Enrichment in n-3 fatty acids was observed at both 4 and 8 weeks of treatment, including a greater 
abundance of elongation products. These data clearly argue in favour of an effective incorporation 
of n-3 fatty acids in the liver, as also indicated by the increased hepatic expression of PPAR-α. 
While previous studies have indicated that PPAR-α limits inflammation in different models of 
steatohepatitis, including the MCD diet model [32-34], in the present study inflammation was 
actually increased in the n-3 PUFA group in spite of an effective increase in PPAR- α expression. 
Other possible mechanisms may contribute to increased inflammation in mice receiving n-3 PUFA. 
At difference with the data of Lee et al. [29], we observed a longer lasting and more severe 
elevation in aminotransferase levels in these mice. This was associated with increased levels of pro-
inflammatory cytokines pivotally involved in the pathogenesis of steatohepatitis, including CCL2, 
which is known to play a pivotal role in the recruitment of different leucocyte populations to sites of 
injury [15], and TNF-alpha. This latter cytokine, considered of pivotal relevance in the pathogenesis 
of steatohepatitis [23], was found to be two times higher in mice receiving a MCD diet together 
with n-3 PUFA supplementation. These changes in cytokines implicated in the pathogenesis of liver 
inflammation represent a relevant mechanism by which n-3 PUFA amplify the inflammatory 
process in this model. Of note, the elevation of these factors and signs of more severe inflammation 
were already present at 4 weeks, whereas more elevated ALT were observed at 8 weeks. This time 
course suggests that increased inflammation was likely responsible for the maintenance of cellular 
injury, rather than the reverse sequence of events. 
Recent data in patients with nonalcoholic steatohepatitis indicate that the presence of inflammation 
in the initial biopsy predicts the likelihood to progress to advanced fibrosis [35], and this clinical 
observation is supported by experimental studies where modulation of inflammation resulted in the 
down-regulation of fibrogenesis (reviewed in Refs [23]). In the present study, significantly higher 
fibrosis scores accompanied the remarkable increase in inflammation observed upon n-3 PUFA 
administration after 8 weeks of treatment. Of note, this was associated with up-regulated expression 
of genes involved in fibrogenesis, such as TGF-beta and TIMP-1, but not type I procollagen, 
suggesting a prevalent role of reduced extracellular matrix degradation, rather than increased matrix 
deposition in mice exposed to n-3 PUFA. To our knowledge, this is the first report indicating a 
modulation of the fibrogenic process by PUFA in experimental steatohepatitis, demonstrating that 
not only inflammatory aspects, but long-term progression may be affected by dietary manipulation. 
Along these lines, portal pressure was only slightly modified by the MCD diet associated with OO 
supplementation, whereas it markedly and significantly increased in mice receiving n-3 PUFA. 
While the more severe fibrosis stage observed in this latter group of mice may be a likely 
explanation of this finding, the possible role of inflammatory infiltration should not be overlooked, 
as inflammation has been recognized as a relevant mechanism leading to portal hypertension [36]. 
Whatever the mechanism involved, the increase in portal pressure in mice treated with a MCD diet 
and n-3 PUFA reinforces the concept that this combination accelerates damage and repair in mice 
with experimental steatohepatitis. 
Several studies and metanalyses have indicated that supplementation with n-3 fatty acids limits 
hepatic triglyceride accumulation and lowers ALT levels in patients with NAFLD, while no 
definitive evidence has been obtained supporting an anti-inflammatory action in humans with 
NASH [10], and larger studies are underway. However, we did not observe any change in the 
steatosis score, similarly to other studies [29], including one where fish oil induced only a modest 
albeit significant decrease in intrahepatic triglyceride accumulation, but no change in the steatosis 
score [22]. The pathogenesis of steatosis in the MCD model, based on reduced assembly and 
secretion of VLDL, is largely different from the one observed in human NAFLD, which is mostly 
related to excess lipolysis and de novo lipogenesis. Thus, it is not surprising that n-3-mediated 
mechanisms operating in purely metabolic steatosis were not effective in this context. On the other 
hand, the use of a MCD diet represents a limitation of this study, because of its poor 
pathophysiological similarity to human NASH. 
The results of our experimental study confirm that dietary intervention with specific nutrients may 
effectively modulate the course and progression of steatohepatitis, although the effects of n-3 PUFA 
were different from those expected in therapeutic human trials. While additional data are warranted 
to establish the final impact of n-3 PUFA supplementation on the outcome of patients with 
steatohepatitis, the results of the present study suggest that careful monitoring and some extra 
caution should be applied when administering n-3 PUFA to subjects with active hepatic 
inflammation. 
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